Jerome Lande - CONMED Independent Director
| CNMD Stock | USD 62.74 0.77 1.24% |
Director
Mr. Jerome J. Lande is Independent Director of Company. As of April 4, 2016, Mr. Lande became Head of Special Situations for Scopia Capital Management L.P. and as of January 1, 2018 also became a Partner of Scopia. Prior to Scopia, Mr. Lande was the Managing Partner of Coppersmith Capital, which he cofounded in April 2012. Previously, Mr. Lande was a partner at MCM Capital Management, LLC, from January 2006 until February 2012, and served as an Executive Vice President at MCM from January 2005 until he left the company. MCM was the general partner of MMI Investments, L.P., a smallcap deep value fund where Mr. Lande was responsible for all areas of portfolio management. He served as a Vice President of MCM from February 2002 to January 2005 and as an Associate from January 1999 to February 2002. Mr. Lande served as Corporationrationrate Development Officer of Key Components, Inc., a global diversified industrial manufacturer that was formerly an SEC reporting company, from January 1999 until its acquisition by Actuant Corporation in February 2004. Mr. Lande also serves on the Board of Directors, Audit and Finance Committee for Itron, Inc. since 2014.
| Age | 45 |
| Tenure | 11 years |
| Address | 11311 Concept Boulevard, Largo, FL, United States, 33773-4908 |
| Phone | 727 392 6464 |
| Web | https://www.conmed.com |
Jerome Lande Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jerome Lande against CONMED stock is an integral part of due diligence when investing in CONMED. Jerome Lande insider activity provides valuable insight into whether CONMED is net buyers or sellers over its current business cycle. Note, CONMED insiders must abide by specific rules, including filing SEC forms every time they buy or sell CONMED'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jerome Lande over six months ago Acquisition by Jerome Lande of 558 shares of Itron subject to Rule 16b-3 |
CONMED Management Efficiency
The company has return on total asset (ROA) of 0.0432 % which means that it generated a profit of $0.0432 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1474 %, meaning that it created $0.1474 on every $100 dollars invested by stockholders. CONMED's management efficiency ratios could be used to measure how well CONMED manages its routine affairs as well as how well it operates its assets and liabilities. As of February 26, 2025, Return On Tangible Assets is expected to decline to 0.08. In addition to that, Return On Capital Employed is expected to decline to 0.09. At present, CONMED's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 122.2 M, whereas Net Tangible Assets are projected to grow to (642.7 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Richard Breeden | STERIS plc | 70 | |
| David Lewis | STERIS plc | 75 | |
| Cheryl Capps | Integer Holdings Corp | 59 | |
| Nirav Shah | STERIS plc | 47 | |
| Donald Spence | Integer Holdings Corp | 67 | |
| Sheila Antrum | Integer Holdings Corp | 62 | |
| Christopher Holland | STERIS plc | 54 | |
| James Tobin | Globus Medical | 75 | |
| Stephanie Zhadkevich | iRhythm Technologies | N/A | |
| Loyal Wilson | STERIS plc | 70 | |
| Steve Zarrilli | Globus Medical | 57 | |
| Aimee Weisner | Glaukos Corp | 51 | |
| David Hoffmeister | Glaukos Corp | 66 | |
| Jacqueline Kosecoff | STERIS plc | 71 | |
| Pamela Bailey | Integer Holdings Corp | 72 | |
| Mark Foley | Glaukos Corp | 55 | |
| Saqib Iqbal | Si Bone | N/A | |
| Joel Suiter | SurModics | N/A | |
| Duncan Nichol | STERIS plc | 76 | |
| Michael Wood | STERIS plc | 74 | |
| Ann Rhoads | Globus Medical | 55 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0432 |
CONMED Leadership Team
Elected by the shareholders, the CONMED's board of directors comprises two types of representatives: CONMED inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CONMED. The board's role is to monitor CONMED's management team and ensure that shareholders' interests are well served. CONMED's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CONMED's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Beyer, President of CONMED International | ||
| John Ferrell, Executive Resources | ||
| Todd CPA, CFO VP | ||
| Laverne Council, Independent Director | ||
| Todd Garner, Chief Financial Officer, Executive Vice President | ||
| David Murray, President Electrosurgery | ||
| Shanna Cottiosmanski, Executive Vice President - Information Technology & CIO | ||
| Brent Lalomia, Executive Affairs | ||
| John Workman, Independent Director | ||
| Charles Farkas, Independent Director | ||
| Barbara Schwarzentraub, Independent Director | ||
| Terence Berge, Vice President and Corporate Controller | ||
| Kimberly Lockwood, Interim Controller | ||
| Peter Shagory, Executive Vice President - Strategy and Corporate Development | ||
| Heather Cohen, Executive Vice President - Human Resources, Secretary | ||
| Stanley Peters, Vice President and General Manager - U.S. Advanced Surgical | ||
| Hollie Foust, General Secretary | ||
| Johonna CPA, VP Treasurer | ||
| Jerome Lande, Independent Director | ||
| Daniel Jonas, Executive Vice President - Legal Affairs, General Counsel, Secretary | ||
| Richard Glaze, Chief Officer | ||
| David Bronson, Independent Director | ||
| Brian Concannon, Independent Director | ||
| Johonna Pelletier, Treasurer and Vice President - Tax | ||
| Curt Hartman, Chairman of the Board, President, Chief Executive Officer | ||
| Stanley III, President Technologies | ||
| Sarah Oliker, Assistant General Counsel, Assistant Secretary | ||
| Daniel Esq, Special Secretary | ||
| Mark Tryniski, Independent Chairman of the Board | ||
| John Kennedy, Vice President and General Manager - U.S. Endoscopic Technologies | ||
| Martha Aronson, Lead Independent Director |
CONMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CONMED a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0432 | ||||
| Profit Margin | 0.10 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 2.8 B | ||||
| Shares Outstanding | 30.91 M | ||||
| Shares Owned By Insiders | 1.44 % | ||||
| Shares Owned By Institutions | 98.56 % | ||||
| Number Of Shares Shorted | 846.97 K | ||||
| Price To Earning | 188.03 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CONMED is a strong investment it is important to analyze CONMED's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CONMED's future performance. For an informed investment choice regarding CONMED Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CONMED. If investors know CONMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CONMED listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.028 | Dividend Share 0.8 | Earnings Share 4.25 | Revenue Per Share | Quarterly Revenue Growth 0.058 |
The market value of CONMED is measured differently than its book value, which is the value of CONMED that is recorded on the company's balance sheet. Investors also form their own opinion of CONMED's value that differs from its market value or its book value, called intrinsic value, which is CONMED's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CONMED's market value can be influenced by many factors that don't directly affect CONMED's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CONMED's value and its price as these two are different measures arrived at by different means. Investors typically determine if CONMED is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CONMED's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.